Wedbush Equities Analysts Reduce Earnings Estimates for VIGL

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Investment analysts at Wedbush cut their FY2027 EPS estimates for Vigil Neuroscience in a research report issued on Thursday, May 22nd. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($2.13) per share for the year, down from their prior estimate of ($1.53). Wedbush has a “Hold” rating and a $8.00 price objective on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share. Wedbush also issued estimates for Vigil Neuroscience’s FY2028 earnings at ($2.39) EPS and FY2029 earnings at ($1.18) EPS.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04.

A number of other brokerages have also issued reports on VIGL. JMP Securities reiterated a “market perform” rating on shares of Vigil Neuroscience in a research note on Thursday. Citigroup lowered shares of Vigil Neuroscience to a “market perform” rating in a research note on Thursday. HC Wainwright dropped their price target on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, March 14th. Mizuho lowered shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Friday. Finally, Guggenheim set a $8.00 price target on shares of Vigil Neuroscience and gave the stock a “neutral” rating in a research note on Thursday. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Vigil Neuroscience currently has a consensus rating of “Hold” and an average price target of $13.00.

Vigil Neuroscience Stock Up 0.1%

Shares of Vigil Neuroscience stock opened at $7.89 on Monday. Vigil Neuroscience has a 52-week low of $1.31 and a 52-week high of $7.95. The company’s 50-day simple moving average is $2.19 and its 200-day simple moving average is $2.28. The firm has a market cap of $368.24 million, a price-to-earnings ratio of -3.83 and a beta of 1.90.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BVF Inc. IL grew its position in Vigil Neuroscience by 121.3% during the first quarter. BVF Inc. IL now owns 4,013,633 shares of the company’s stock worth $7,144,000 after buying an additional 2,200,000 shares during the period. 683 Capital Management LLC grew its position in Vigil Neuroscience by 24.3% during the first quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company’s stock worth $3,097,000 after buying an additional 340,000 shares during the period. Aberdeen Group plc grew its position in Vigil Neuroscience by 226.3% during the first quarter. Aberdeen Group plc now owns 1,724,520 shares of the company’s stock worth $3,070,000 after buying an additional 1,196,048 shares during the period. Blair William & Co. IL grew its position in Vigil Neuroscience by 219.1% during the first quarter. Blair William & Co. IL now owns 1,033,577 shares of the company’s stock worth $1,840,000 after buying an additional 709,677 shares during the period. Finally, Ensign Peak Advisors Inc grew its position in Vigil Neuroscience by 16.1% during the fourth quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company’s stock worth $1,195,000 after buying an additional 97,580 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.